Pharmaceutica Analytica Acta

Controlled release ocular nanosuspension of acyclovir ophthalmic delivery

5^th International Conference and Exhibition on Pharmaceutics & Novel Drug Delivery Systems

March 16-18, 2015 Crowne Plaza, Dubai, UAE

Shashidhar Kerur, K R Alagawadi and F V Manvi

Posters & Accepted Abstracts: Pharm Anal Acta

Abstract:

The aim of this study is to formulate a novel ophthalmic nanosuspension (ONS), an alternative carrier system to traditional colloidal carriers for controlled release (CR) of acyclovir (ACV). In the present study, ONS is employed to avoid some of major disadvantages of colloidal carriers systems such as instability in cul de sac and short half life by increasing efficiency of drug encapsulation as well as by CR. A quassi-emulsion solvent evaporation method was used to prepare ACV loaded Eudragit RS 100 ONS with the aim of improved ocular bioavailability and distribution. Five different formulations were prepared and evaluated for pH of ONS, particle size, entrapment efficiency, differential scanning calorimetry (DSC), in vitro release profile, in vivo release studies and stability studies. An average size range of 100 to 300 nm in diameter was obtained and encapsulation efficiency up to 95.0% was observed. In vivo studies showed that ACV concentration in aqueous humor at 8 h was 82.83, 77.49 and 34.15 mg/ml. Stability studies showed a maximum drug content and almost similar in vitro release compared to the initial data found for the sample stored at 4?C. Overall, the study also revealed that ONS was capable of releasing the drug for a prolonged period of time and increased bioavailability.